声明
Acknowledgement
Abbreviations and Definitions
摘要
Abstract
Table of Content
Background
1 Design and Synthesis of 2,4-di-substituted Quinazoline Derivative
1.2 Design and Overview of Disubstituted Quinazoline Derivatives
1.3 Synthesis of 2,4 Dicholoroquinazoline Intermediates Optimization of N-(2-cyano-3-fluorophrnyl)acetamide Synthesis (S-1)
1.4 Synthesis of substituted 2,4 Diehloroquinazoline Intermediates(S-7to S-17)
1.5 Evaluation of Disubstituted Quinazoline HCV Inhibitors (S-18 to S-26)
1.6 SAR Analysis of Diquinazoline Derivatives Inhibiton against HCV 4-Hydrogen Quinazoline-2-Amine Series,Exploration of the 5 Position
1.7 Discussion
1.8 Experimental Section
1.9 Section on Cellular Test Conditions
References
2.Diversity 0riented Synthesis of Azachromone
2.1 Background
2.2 Design of Azachromone Synthetic Route
2.3 Conditions for Synthesis of Azachromone and Data
2.4 Conclusion
2.5 Experimental Section
References
3.Research and Development of HCV Inhibitors(Review)
3.1 Background
3.2 HCV Viral Life Cycle and Potential Targets For HCV Therapy
3.3 NS3/4A Inhibitors
3.3.1 First Generation NS3/4A Inhibitor Boceprevir
3.3.2 Telaprevir,all Alternative NS3/4A Inhibitor
3.3.3 Simeprevir,a Second Generation NS3/4 Inhibitor
3.4 NS5A Inhibitors
3.4.1 Ombitasvir,a Potent NS5A Inhibitor
3.4.2 Ledipasvir a New Class of NS5A Inhibitor
3.5 NS5B Inhibitors
3.5.1 Sofosbuvir,an Anti-HCV Nucleotide Phosphoramidate Prodrug
3.5.2 Dasabuvir,A NS5B Inhibitor
3.6 Combination Drug
3.6.2 Virakirax:Ombitasvir,Paritaprvir,and Ritonavir CombinationTreatment of HCV
3.6.3 Simeprevir,Daclatasvir,and Sofosbuvir Com bination of DAA Treatment for HCV Therapy
3.7 Futu re Prospects
References